DedrickR.L., MyersC.E., BungayP.M., DevitaV.T.Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.Cancer Treat Rep1978; 62: 1–11.
3.
AlbertsD.S., LiuP.Y., HanniganE.V., O'TooleR., WilliamsS.D., YoungJ.A.Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.N Engl J Med1996; 335: 1950–5.
4.
ScheithauerW., KornekG.V., MarczellA., KarnerJ., SalemG., GreinerR.Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy in resected colon carcinoma.Br J Cancer1998; 77: 1349–54.
5.
DedrickR.L., FlessnerM. F.Review. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.J Natl Cancer Inst1997; 89: 480–7.
6.
McArdleC.S., KerrD.J., O'GormanP., WotherspoonH.A., WarrenH., WatsonD.Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma.Br J Cancer1994; 70: 762–6.
7.
KerrD.J., YoungA.M., NeoptolemosJ.P., ShermanM., Van-GreeneP., StanleyA.Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution.Br J Cancer1996; 74: 2032–5.
8.
JoelS P., GrayJ., HalsteadF., RichardsF., GilbertJ., WilkinsonV.The pharmacokinetics of single-dose intraperitoneal 5-fluorouracil (5-FU) in saline and icodextrin.Br J Cancer1999; 80(Suppl 2): 94.
9.
GilbertJ.A., PeersE.M., BrownC.B., BeranY.IP fluid dynamics of 4% icodextrin (ICO) in non-ESRD patients (Abstract).Perit Dial Int1999; 19(Suppl 1): S79.
10.
ShaunakS., ThorntonM., JohnS., TeoI., PeersE., MasonP.Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS.AIDS1998; 12: 399–409.
11.
DeshaneJ., SeigalG.P., WangM., WrightM., BucyR.P., AlvarezR.D.Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single chain antibody for ovarian cancer gene therapy.Gynecol Oncol1997; 64: 378–85.
12.
HwangR.F., GordonE.M., AndersonW.F., ParckhD.Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene.Surgery1998; 124: 143–51.
MartisL., ChenC., MoberlyJ.B.Peritoneal dialysis solutions for the 21st century.Artif Organs1998; 22: 13–16.
16.
HoffC.M., ShockleyT.R.The potential of gene therapy in the peritoneal cavity.Perit Dial Int1999; 19(Suppl 2): S202–7.
17.
MenziesD., EllisH.Intestinal obstruction from adhesions: how big a problem?Ann R Coll Surg Engl1990; 72: 60–3.
18.
EllisH., MoranB.J., ThompsonJ.N., ParkerM.C., WilsonM.S., MenziesD.Adhesion-related hospital re-admissions after abdominal and pelvic surgery: a retrospective cohort study.Lancet1999; 353: 1476–80.
19.
BeckD.E., OpelkaF.G., BaileyH.R., RauhS.M., PashosC.L.Incidence of small-bowel obstruction and adhesiolysis after open colorectal and general surgery.Dis Colon Rectum1999; 42: 241–8.
20.
HolmdahlL.Making and covering of surgical footprints.Lancet1999; 353: 1456–7.
